Get started

IPIX

IPIX INNOVATION PHARMACEUTICALS : 500% GAIN BEFORE MAJOR RALLYPLEASE FOLLOW AND LIKE IF YOU APPRECIATE THIS CONTENT AND FOR CONTINUOUS UPDATES + ANALYSIS. COMMENT BELOW AND LET ME KNOW YOUR OPINION. THANK YOU IPIX looks poised to make a big move. A measured move of the bull flag would bring IPIX to about $.25 cents +/- Their trademark drug Brilacidin is making serious breakthroughs and I believe this Company is about to explode. I see this company going to hundreds of dollars when they make a serious breakthrough and it can be marketed after trials are done. I am loading up on this company for sure. This is not financial advice this is just my opinion. Good luck out there. Below is a copy and paste quick description of the company. Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies with anti-inflammatory, antibiotic, antiviral, dermatology and oncology applications. The Company owns the right to numerous drug compounds, including Brilacidin, its lead drug in a class of compounds known as defensin-mimetics and Kevetrin (thioureidobutyronitrile), which is its lead anti-cancer compound. The Company's clinical trials focused on evaluating its drug candidates, including Kevetrin for the treatment of cancers and Brilacidin for treatments of Acute Bacterial Skin and Skin Structure Infection (ABSSSI), prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative colitis. The Company is focused on developing small molecule therapies to treat diseases in the areas of inflammatory diseases, cancer, dermatology and anti-infectives.
OTC:IPIXLong
by Bitgolder
$IPIX Pulls Back to Confluence Support Zone in Upward TrendIPIX is a strong Coronavirus therapeutics opportunity coming into key trendline support just as the Ichimoku Cloud indicator is signaling "buy the dip!" at range level support, which is working in confluence with the trendline at current levels and just underneath. Oscillators are also signaling the current opportunity as price reaches short-term oversold levels. -------------------------------------------- Innovation Pharmaceuticals Inc (OTCMKTS:IPIX) is part of a small group of stocks bucking the recent broad market crash brought on by the rapid pandemic spread of the COVID-19 disease. This group of stocks represents a unifying characteristic: the outbreak is an opportunity. In this case, that opportunity is relatively straightforward. IPIX has been developing Brilacidin, a versatile compound that belongs to a new and significant class called defensin-mimetics. Recent research has emerged that suggests this compound may prove useful as a therapeutic tool as we fight to defend our sick against this aggressive disease. This isn’t a vaccine. It’s a potential power-tool for the immune system to leverage in its battle for those with the disease. The big point here is that this is about the fight we have in front of us, rather than the one we wish we had. We wish we had a “containment fight” – where only a small group of isolated individuals were infected and we could fence them off and spare the rest of the world. Now, leading epidemiologists (and the WHO and CDC) are starting to relinquish the idea of containment, favoring preparation. So, with containment lost, we wish we had a “vaccination fight” – where we were racing against the clock to get a viable vaccine out in the weeks ahead, putting up a microbial suit of armor to spare the majority of the world from risk of serious COVID-19 infection. Unfortunately, we have a “therapeutic fight”, where we can expect lots of people will get this disease, and it will be a long time (maybe 12-18 months) before we have a viable vaccine candidate. In that type of fight, what we will be looking for are tools to help reduce the severity of bad cases – to compress the case fatality rate by arming our bodies with better weapons. In that vein, IPIX just announced that testing of Brilacidin as a novel experimental treatment against COVID-19 is scheduled to commence at one of the twelve U.S. Regional Biocontainment Labs (RBLs) this week.
OTC:IPIXLong
by GregFolin
1